Business Description
Pharma Equity Group AS
ISIN : DK0061155009
Share Class Description:
OCSE:PEG: Class ATotal Employee Number:
5Compare
Compare
Traded in other countries / regions
PEG.Denmark0REU.UK IPO Date
2003-06-25Description
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.32 | |||||
Debt-to-EBITDA | -0.34 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.6 | |||||
3-Year EPS without NRI Growth Rate | -26 | |||||
3-Year FCF Growth Rate | -67.1 | |||||
3-Year Book Growth Rate | -74.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.36 | |||||
9-Day RSI | 44.64 | |||||
14-Day RSI | 47.41 | |||||
3-1 Month Momentum % | -20.66 | |||||
6-1 Month Momentum % | -37.98 | |||||
12-1 Month Momentum % | -42.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.33 | |||||
Quick Ratio | 4.33 | |||||
Cash Ratio | 0.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -220.5 | |||||
Shareholder Yield % | 14.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -78.07 | |||||
ROA % | -50.56 | |||||
ROIC % | -54.68 | |||||
3-Year ROIIC % | 43.52 | |||||
ROC (Joel Greenblatt) % | -6811.51 | |||||
ROCE % | -57.06 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.8 | |||||
Price-to-Tangible-Book | 3.99 | |||||
EV-to-EBIT | -4.42 | |||||
EV-to-EBITDA | -4.48 | |||||
EV-to-FCF | -5.92 | |||||
| Price-to-Net-Current-Asset-Value | 3.99 | |||||
Earnings Yield (Greenblatt) % | -22.62 | |||||
FCF Yield % | -18.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharma Equity Group AS Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.02 | ||
| Beta | 0.2252 | ||
| 3-Year Sharpe Ratio | -0.76 | ||
| 3-Year Sortino Ratio | -0.91 | ||
| Volatility % | 50.24 | ||
| 14-Day RSI | 47.41 | ||
| 14-Day ATR (kr) | 0.00697 | ||
| 20-Day SMA (kr) | 0.08454 | ||
| 12-1 Month Momentum % | -42.71 | ||
| 52-Week Range (kr) | 0.0602 - 0.15 | ||
| Shares Outstanding (Mil) | 1,227.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharma Equity Group AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharma Equity Group AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-14 | In 31 days | ||
| General meeting for 2025 | 2026-04-16 15:30 | 0.08 (-10.71%) | ||
| Annual report for 2025 | 2026-03-25 | 0.09 (-3.18%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.12 (+2.07%) | ||
| General meeting for 2024 | 2025-04-16 15:30 | 0.09 (-8.07%) | ||
| Annual report for 2024 | 2025-03-20 | 0.14 (+0.70%) | ||
| Third quarter earnings results for 2024 | 2024-11-15 | 0.18 (+4.65%) | ||
| Second quarter earnings results for 2024 | 2024-08-16 | 0.27 (-3.60%) | ||
| 2:1 Stock Split | 2023-01-27 | 0.53 (+3.92%) | ||
| 0.1:1 Stock Split | 2019-10-29 | 2.60 (+2.36%) |
Show
Entries
Pharma Equity Group AS Frequently Asked Questions
What is Pharma Equity Group AS(OCSE:PEG)'s stock price today?
The current price of OCSE:PEG is kr0.08. The 52 week high of OCSE:PEG is kr0.15 and 52 week low is kr0.06.
When is next earnings date of Pharma Equity Group AS(OCSE:PEG)?
The next earnings date of Pharma Equity Group AS(OCSE:PEG) is 2026-08-14.
Does Pharma Equity Group AS(OCSE:PEG) pay dividends? If so, how much?
Pharma Equity Group AS(OCSE:PEG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Pharma Equity Group AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers